Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4974-4981

  Basu, Anupam ^a   Menicucci, Gina ^a   Maestas, Joann ^a   Das, Arup ^a,b   McGuire, Paul ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD51 ANTIGEN; OXYGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN; MESSENGER RNA; SERINE PROTEINASE INHIBITOR; SERPINE2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RETINA CELL; RETINA NEOVASCULARIZATION; RETINOPATHY; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; DISEASE MODEL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; METABOLISM; MOUSE MUTANT; NEWBORN; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; HUMANS; INFANT, NEWBORN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXYGEN; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERPINS; UP-REGULATION; VITRONECTIN;

EID: 70349581639     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3619     Document Type: Article

References (47)

1. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retinal Eye Res. 2003;22:721-748.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
4. Ritter MR, Banin E, Moreno SK, Aguilar E, Dorrell MI, Friedlander M. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J Clin Invest. 2006;116:3266-3276.
5. Friedlander M, Dorrell MI, Ritter MR, et al. Progenitor cells and retinal angiogenesis. Angiogenesis. 2007;10:89-101.
6. Grant MB, Stratford May W, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002;8:607-612.
7. Sengupta N, Caballero S, Mames RN, et al. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:4908-4913.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
9. Das A, Fanslow W, Cerretti D, Warren E, Talarico N, McGuire PG. Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab Invest. 2003;83:1637-1645.
10. Colombo ES, Menicucci G, McGuire PG, Das A. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci. 2007; 48:1793-1800.
11. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999;40:809-813.
12. McGuire PG, Jones TR, Talarico N, Warren E, Das A. The urokinase/ urokinase receptor system in retinal neovascularization: inhibition by Å6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci. 2003;44:2736-2742.
13. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97: 336-342.
14. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA/PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71:411-421.
15. Zhang JC, Sakthivel R, Kniss D, Graham CH, Strickland DK, McCrae KR. The low density lipoprotein receptor-related protein/alpha2- macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells. J Biol Chem. 1998;273: 32273-32280.
16. Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1 deficient endothelial cells. J Biol Chem. 2006;281:22527-22536.
17. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem. 2001;276:33964-33968.
18. Lambert V, Munaut C, Carmeliet P, et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci. 2003;44:2791-2797.
19. Lambert V, Munaut C, Noël A, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15:1021-1027.
20. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood. 1996;87:4718-4722.
21. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K, Johnsen M. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice Oncogene. 2003;22:4389-4397.
22. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem. 2001;276:8135-8141.
23. Maud J, Maillard C, Lecomte J, et al. Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type 1. Am J Pathol. 2007;171:1369-1380.
24. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 2003;10:541-544.
25. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCt method. Methods. 2001;25:402-408.
27. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003;160:781-791.
28. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985;260:11581-11587.
29. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J Biol Chem. 1988;263:2358-2363.
30. Daniel A, Selvi Palaniappan L, Stefansson S, et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: implications for the regulation of pericellular proteolysis. J Biol Chem. 1997; 272:7676-7680.
31. Estreicher A, Mulhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990;111:783-792.
32. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA: serpine complexes. EMBO J. 1997;16:2610-2620.
33. Liao H, Hyman MC, Lawrence DA, Pinsky DJ. Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1α and C/EBPα. FASEB J. 2007;21:935-949.
34. Gram J, Jespersen J. Induction and possible role of fibrinolysis in diabetes mellitus. Semin Thromb Hemost. 1991;17:412-416.
35. Small M, Kluft C, MacCuish AC, Lowe GD. Tissue plasminogen activation inhibition in diabetes mellitus. Diabetes Care. 1989;12: 655-658.
36. Grant MB, Spoerri PE, Player DW, et al. Plasminogen activator inhibitor (PAI-1) overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci. 2000;41:2296-2302.
37. Grant MB, Ellis EA, Caballero S, Mames RN. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. Exp Eye Res. 1996;63:233-244.
38. Penn JS, Rajaratnam VS. Inhibition of retinal neovascularization by intravetreal injection of human rPAI-1 in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003;44:5423-5429.
39. Fruttiger M. Development of the mouse retinal vasculature: angiogenesis vs. vasculogenesis. Invest Ophthalmol Vis Sci. 2002;43: 522-527.
40. Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996;37:290-299.
41. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol. 2001;152:777-784.
42. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem. 1996;271:12716-12723.
43. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost. 2004;3:35-45.
44. Okumura Y, Kamikubo Y, Curriden SA, et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem. 2002;277:9395-9404.
45. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature. 1996;383:441-443.
46. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21:1104-1117.
47. Carriero MV, Del Vecchio S, Capozzoli M, et al. Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinasedependent cell migration in breast cancer. Cancer Res. 1999;59: 5307-5314.